Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Back
Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, highlight treatment trends and key data emerging in the field of myelodysplastic syndromes.
Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024
Episodes
All
All
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
3
Dr Viansone on De-Escalating Chemotherapy Type and Duration in HER2-Positive Breast Cancer
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5